Cargando…
Perioperative systemic therapies for non-small-cell lung cancer: Recent advances and future perspectives
The mainstay of treatment for early-stage non-small-cell lung cancer (NSCLC) is surgical resection. Traditionally, chemotherapy has been used perioperatively in locally extensive disease to improve the oncologic outcomes of surgery, with a 5-year absolute survival benefit of approximately 5%. In rec...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895369/ https://www.ncbi.nlm.nih.gov/pubmed/36743902 http://dx.doi.org/10.3389/fsurg.2022.1126486 |